As the world awakens to consider its new normal in the midst of the COVID-19 pandemic, digital technology is providing new hope in the fight against skin cancer, a disease that doesn’t respond to the idea of a pause.
AMSTERDAM, 7 May 2020 – Spring and warm weather are here to stay for the coming months. Despite the fact that many aspects of our daily lives have changed drastically, responsible sun behaviour and timely detection of skin cancer remain more important than ever.
SkinVision, the leading app for early skin cancer detection, recently achieved three important ISO certifications. The British Standards Institution (BSI), awarded SkinVision ISO 13485:2016 for its quality management system. Additionally, BSI awarded the company ISO 27001:2013 for information security management, as well as the Dutch national standard NEN 7510:2017, which includes additional requirements to ISO 27001:2013, specifically for healthcare providers in the Netherlands, where SkinVision is based.
Amsterdam, 12 September 2019 – An international group of researchers working with Erasmus University Medical Center (Erasmus MC) in the Netherlands determined that SkinVision – the first CE-marked skin cancer application based on extensive clinical trials – has a sensitivity of 95.1% in detecting the most common forms of skin cancer.
Smartphone App for Skin Cancer Risk Selected to Join DigitalHealth.London Accelerator
SkinVision, a mobile application driving early skin cancer detection by empowering individuals to monitor their skin for early signs of skin cancer, has been selected to join the DigitalHealth.London Accelerator.
Dutch Health Insurer CZ and SkinVision partner to create an impact in early skin cancer detection
For about two decades, the number of skin cancers across Europe has been rising steadily. Every year more than 200,000 people in Germany are diagnosed
AMSTERDAM, July 30 2018 — The SkinVision team is thrilled to announce the investment of $US7.6 million in the company to support their journey of bringing convenient, accurate and quick recognition of skin cancer. This funding round has been supported by current shareholders LEO Pharma, PHS Capital and a number of new high net worth impact investors.